Hypertension (HT) is the most important modifiable risk factor for stroke (both ischemic and hemorrhagic types). In the hyperacute phase, a majority of patients shows an elevated blood pressure (BP) at the time of presentation because of sympathetic hyperactivity or a physiological response to tissue ischemia. Therefore, BP may decrease spontaneously in a few hours and may drop further when complete recanalization is achieved. In stroke guidelines, an elevated BP is usually left untreated up to a systolic BP (SBP) of 220 mm Hg and a diastolic BP of 120 mm Hg. This recommendation is based on the BP level that corresponds to the upper limit of the pressure autoregulation zone above which cerebral blood flow is directly dependent on BP. However, in patients in whom administration of recombinant tissue-type plasminogen activator is indicated, BP should be controlled to a level < 185/110 mm Hg before infusion and should be maintained at levels < 180/105 mm Hg to limit the risk of intracerebral hemorrhage (ICH). In cases where endovascular thrombectomy is considered, the optimal intra- and postprocedural BP target have not yet been clearly identified. Expert opinion recommends that intra-procedural BP reduction could be associated with a risk of poor outcomes, and therefore, SBP may be reduced only to 120 to 140 mm Hg after successful reperfusion therapy. However, this recommendation is primarily based on observational studies and requires validation in prospective trials. It has been observed that in patients presenting with an ICH, there is no perihematomal penumbra noted and rapid BP reduction is generally well tolerated without a risk of neurological worsening. Multiple trials describing acute reduction of BP recommend SBP reduction only to 140 mm Hg because while there is no benefit of better functional outcomes below that level, there exists a definite risk of increased renal complications.
stroke showed only a mild elevation of BP. Among the different subtypes, lacunar stroke was associated with a higher level of BP than the levels associated with other subtypes. All these findings suggest that HT significantly affects small perforating vessels leading to lacunar infarcts or ICH.

It has been observed that an elevated BP may spontaneously decrease over a few days after presentation. A persistent elevation of BP is associated with cardiac complications, hemorrhagic transformation (HTF), hemotoma expansion (HE), or enlargement of perihematomal edema—complications that are associated with poor functional outcomes. Therefore, although a certain degree of BP lowering might be required, the optimal target level and rapidity of BP reduction has not clearly been identified in patients with ischemic or hemorrhagic stroke. We present a review of current literature and summarize the goals of BP management in patients presenting with acute ischemic stroke and ICH.

Hemodynamic Changes in Acute Stroke

Autoregulation

Cerebral autoregulation (CA) is a mechanism that maintains constant cerebral blood flow (CBF) regardless of changes in cerebral perfusion pressure (CPP) or mean arterial pressure (MAP). When CA is intact, a drop in CPP may induce cerebral vasodilation via a decrease in vascular resistance to maintain constant CBF. Real-time assessment of this dynamic mechanism of CA may require sophisticated tools for multimodality neuromonitoring. However, in real-world clinical practice, it is difficult to assess the status of CA in stroke patients without continuous monitoring. Based on studies performed in patients with severe traumatic brain injury, we extrapolate that CA failure might contribute to further brain injury in stroke patients and that its severity is directly proportional to stroke severity. It can be hypothesized that a certain degree of impairment in CA exists in patients with severe stroke.

When the MAP ranges between 50 and 150 mm Hg, a stable CBF is maintained if CA is intact. An increase in MAP > 150 mm Hg may lead to forced dilation of cerebral blood vessels and cerebral hyperperfusion in the autoregulatory breakthrough zone. On the contrary, a drop in MAP to < 50 mm Hg results in a passive collapse of blood vessels and leads to ischemia secondary to hypoperfusion. CA is known to be altered/defective in patients presenting with severe stroke; therefore, an abrupt BP drop in such patients could lead to a concomitant decrease in CBF, which may predispose them to secondary cerebral ischemia.

Acute Ischemic Stroke

Mechanisms of Blood Pressure Elevation

Elevated BP is commonly observed in patients presenting with acute ischemic stroke, especially in a setting of a prior history of HT. An exact pathomechanism to explain the BP elevation remains unclear. However, proposed pathomechanisms are a stress response secondary to sympathetic hyperactivity, disturbed parasympathetic activity, elevated levels of circulating catecholamines or brain natriuretic peptide, tissue ischemia, or a combination of the above factors. In patients demonstrating large vessel occlusion, an elevated BP may return to baseline level following complete recanalization, suggesting that BP elevation is closely linked to brain tissue ischemia. Therefore, BP elevation by itself might be beneficial in augmenting CBF in the penumbra in patients with ischemic stroke. Clinical data combined with perfusion imaging have shown that a relative filling delay decreases as the BP increases, suggesting the augmentation of cerebral perfusion via leptomeningeal collaterals. To summarize, the BP surge observed in cases of acute ischemic infarction may be a natural response to tissue ischemia.

American Stroke Society Guideline Suggestion

Guidelines suggest that a level of 220/120 mm Hg, which is the upper limit of BP corresponding to adequate function of CA, is usually considered an acceptable level of BP elevation. BP elevation beyond this level might be associated with hyperperfusion syndrome or HTF in the ischemic tissue. As mentioned earlier, the reference range of intact CA is a MAP between 50 and 150 mm Hg. The recommended BP level of 220/120 mm Hg can be adjusted off of a MAP of 150 mm Hg.

Points to Consider with Use of Intravenous Thrombolysis

Symptomatic ICH must be recognized as the most serious complication when considering infusion of recombinant tissue-type plasminogen activator (tPA) (< Fig. 1). When administration of tPA is considered, BP should be controlled to a level < 185/100 mm Hg and should be maintained at a level < 180/105 mm Hg even after completion of infusion. In a pilot dose-finding study performed in patients with ischemic stroke, based on a previous study examining administration of tPA in patients with myocardial infarction, the original exclusion criterion of BP elevation was a level of 200/120 mm Hg. However, three patients demonstrated symptomatic ICH in the high-dose tier (0.95–1.08 mg/kg), and all patients showed BP level > 160/90 mm Hg, while 38% (27 of 71) patients without ICH showed BP > 160/90 mm Hg. Therefore, the protocol was amended to exclude patients with MAP > 133 mm Hg, which could be interpreted as a BP reading of 185/110 mm Hg. Subsequent analysis showed that the dose of infused tPA and the level of DBP were significantly associated with ICH after intravenous (IV) thrombolysis. Following these findings, strict BP control was recommended in patients who were administered tPA.

Some patients may need antihypertensive drugs to maintain BP < 185/110 mm Hg for safe administration of tPA infusion. The aforementioned study showed that BP reduction to initiate tPA treatment does not affect adverse outcomes in patients with ischemic stroke. A substudy from tPA National Institute of Neurological Disorders and Stroke (NINDS) trial showed that antihypertensive therapy administered prior to tPA was not associated with differences in early or late outcomes. In addition, another study performed by independent investigators showed that antihypertensive treatment prior to tPA infusion was not independently associated with poor neurological outcomes. Among the 427 patients studied, 89 received antihypertensive therapy.
aggressive BP control prior to thrombolysis, 65 received standard BP control, and 273 required no BP control. Although patients requiring BP control scored higher on the National Institutes of Health Stroke Scale (NIHSS), BP reduction was not associated with adverse events after adjusting for baseline characteristics. Therefore, careful attention to and gentle management of BP are warranted in patients presenting with stroke who are considered candidates suitable for tPA treatment.

The Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR) is a prospective multinational register containing data of patients treated with thrombolysis following an acute ischemic stroke. Secondary analysis of data from this monitoring registry has shown that persistently high SBP up to 24 hours after thrombolysis was associated with worse outcomes. Moreover, the relationship between SBP and outcomes showed a U-shaped association suggesting that a higher proportion of patients with SBP 141 to 150 mm Hg demonstrated favorable outcomes defined as a modified Rankin scale (mRS) of 0 to 2 at 3 months. Considering that the SITS-ISTR registry is not a randomized trial, these results are inconclusive, and we can only hypothesize regarding the findings.

The Enhanced Control of Hypertension and Thrombolysis Stroke Study was originally designed to compare two doses of tPA (0.6 vs. 0.9 mg/kg). In this trial, patients with elevated SBP (150–220 mm Hg) were randomly assigned to an intensive BP-lowering group (SBP < 140 mm Hg within 1 hour) and a conventional guideline group (SBP < 180 mm Hg). Choice of antihypertensive used was at the discretion of the treating physicians. The primary outcome regarding tPA dose has already been published; however, data from different BP targets continue and are scheduled to be completed in 2018. Results of this trial may provide an answer regarding the optimal target BP that needs to be achieved after IV thrombolysis.

Endovascular Thrombectomy

No strong data exist regarding target BP after endovascular thrombectomy (EVT). A study involving 674 patients who underwent IV or intra-arterial thrombolysis showed that a J-shaped relationship was identified in terms of the association between BP over the first 24 hours and functional outcomes in patients who failed recanalization, whereas a linear correlation was identified in terms of the association between BP and functional outcome in patients who demonstrated complete recanalization. These findings suggest that recanalization status should be considered an important modifier of neurological outcomes.

Intraprocedural BP drop might be detrimental in patients who undergo EVT. Earlier studies focusing on the type of anesthesia show that general anesthesia (GA) was inferior to conscious sedation (CS) in terms of neurological outcomes in patients presenting with acute large vessel occlusion. However, it is unclear whether anesthesia itself or the ensuing drop in BP was the cause of this finding; most patients who received GA showed a lower BP during EVT. Low BP during an EVT procedure is considered to be an important contributor to poor functional outcomes. A subsequent study comparing GA and CS has since shown that the two anesthesia methods are equivalent in terms of functional outcomes. Based on these results, it can be deduced that a very low BP in nonrecanalized patients might be harmful when undergoing EVT. However, the optimal intraprocedural target BP level has not yet been established. Expert opinions vary with some authors recommending a level of approximately 140 to 160 mm Hg and others recommending a level of 120 to 140 mm Hg.
Moreover, the optimal target BP after complete recanalization has not yet been conclusively established/defined. Modest BP control might be helpful in reducing reperfusion injury or HTF. In a retrospective study that included 228 patients who showed complete recanalization after EVT, patients were categorized into three groups (those without HFT, those with asymptomatic HTF, and those with symptomatic HTF), and mean SBP was compared between these groups. It was observed that patients without HFT showed lower SBP (mean 159 mm Hg) compared with those with asymptomatic HTF (mean SBP 169 mm Hg) and asymptomatic HTF (mean SBP 170 mm Hg) suggesting that lower BP might be associated with a lower risk for HTF. Another study has shown that the BP level after EVT was one of the factors related to functional outcomes at 3 months. Patients with moderate BP control (SBP < 160 mm Hg) showed lower odds for mortality at 3 months than those with permissive HT (SBP < 220 or < 180 mm Hg in cases warranting IV administration of tPA). To summarize, it can be stated that modest BP control might be needed in patients with complete recanalization following EVT, although the optimal target SBP that needs to be achieved warrants further investigation for a definitive answer.

**Blood Pressure Variability**

In addition to absolute BP levels, variability of BP levels may be an independent predictor for poor clinical outcomes. Marked BP variability measured as significant differences in successive variation was shown to be associated with poor functional outcomes (mRS of 3–6), higher rate of mortality, and symptomatic ICH in stroke patients treated with IV tPA.

**Blood Pressure Control in a Nonthrombolysis Setting**

Several observational studies have examined the relationship between BP and outcomes in nonthrombolysis settings. A post hoc analysis of the International Stroke Trial reported that SBP measured immediately after randomization was associated with poor functional outcomes and mortality in 17,398 patients with acute ischemic stroke. The association showed a U-shaped relationship, and SBP of 140 to 179 mm Hg (a nadir at ~150 mm Hg) was associated with the best outcome. A U-shaped relationship has also been demonstrated in another independent study. However, these studies did not focus on the effect of treatment with antihypertensive agents.

Several clinical trials have focused on modulation of BP within several days after onset of an ischemic stroke. The Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS) trial was designed to assess the outcomes of modest BP reduction following administration of candesartan in 342 patients with elevated BP (defined as BP > 220/110 mm Hg within 24 hours after admission or > 180/105 mm Hg between 24 and 36 hours after admission). Candesartan was administered for 7 days after which the BP profile was reviewed. When mean BP was > 135/85 mm Hg, candesartan was continued. Results showed that early use of candesartan after onset of an ischemic stroke significantly improved cardiovascular mortality and morbidity. A subsequent study involving a larger number of patients was performed to validate these results. The Scandinavian Candesartan Acute Stroke Trial was a phase III clinical trial that included 2,029 patients using study protocols that were very similar to the ACCESS trial. However, functional outcomes were not different in patients with or without candesartan treatment. Moreover, patients who were treated with candesartan showed less favorable outcomes at 6 months compared with those who received a placebo. Interestingly, 15% of the included patients were those diagnosed with a hemorrhagic stroke. However, subgroup analysis did not show any benefit even in patients with a hemorrhagic stroke. Moreover, acute BP management using valsartan showed a negative effect on functional outcomes. The Valsartan Efficacy on N modulation of Blood Pressure and Stroke (VENS) trial included 393 patients diagnosed with acute ischemic stroke within 48 hours and showed that early BP lowering was significantly associated with a higher risk for early neurological deterioration. Based on these findings, it can be stated that if BP reduction is a risk factor for poor neurological outcomes, discontinuing the use of antihypertensive agents might be considered in patients with acute ischemic stroke who are currently administered antihypertensives.

The Continue Or Stop post-Stroke Antihypertensives Collaborative Study (COSSACS) trial compared the effect of continuing or stopping antihypertensive drugs for 2 weeks on functional outcomes. The study included 763 patients and continuation of antihypertensives lowered SBP and DBP by 13 and 8 mm Hg, respectively. However, this trial could not conclusively demonstrate the differences in outcomes between the groups probably because of the small number of patients included. The most recent trial that studied the effect of BP lowering was the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS) trial. This study enrolled 4,071 patients with acute ischemic stroke within 48 hours and in whom SBP was measured between 140 and 220 mm Hg. Compared with the placebo group, the active BP lowering group (SBP lowering by 10–25% within a day) did not show benefit in terms of neurological disability at 14 days. Based on these clinical trials, a meta-analysis was performed and concluded that early management of BP in acute ischemic stroke was not associated with better clinical outcomes.

**Brain Edema and Blood Pressure**

Brain edema is one of the major complications known to occur after an acute ischemic stroke. Significant brain edema leads to brain tissue herniation secondary to an elevation in intracranial pressure and subsequent poor neurological outcomes. Cytotoxic edema develops due to energy failure within the first few hours after permanent ischemia and is followed by the development of osmotic edema owing to disruption of the osmotic pressure gradient. Vasogenic edema begins to develop a few days later due to the breakdown of the blood–brain barrier (BBB), which is linked to HTF. In brain tissues with BBB breakdown, hyperperfusion or HT is mechanistically associated with brain edema and HTF. A study has shown that higher SBP was associated with brain edema in patients with acute ischemic and hemorrhagic stroke, which is in agreement with the afore-mentioned statement. Moreover, patients with brain edema showed persistently elevated SBP.
compared with those without brain edema and usually had a spontaneous decline in SBP over time.\textsuperscript{59} A study has investigated the association between BP variability and brain edema. Among the included patients, 75.8\% had presented with ischemic strokes. Development of brain edema was significantly associated with stroke severity and BP variability measured as “time rate” implying the rapidity of SBP change, while the absolute SBP failed to show a statistically significant relationship with brain edema.\textsuperscript{60} A time rate of BP variation of 0.1 mm Hg/min was significantly associated with a 13.9\% increased probability of developing brain swelling.

### Hemorrhagic Transformation
HTF develops in approximately 10 to 15\% of cases of ischemic stroke and is associated with poor functional outcomes.\textsuperscript{61} When HTF produces a mass effect, it leads to symptoms in the patient and is related with neurological deterioration. A high BP has been recognized as a risk factor for HTF.\textsuperscript{62} Moreover, wide fluctuations in BP plays a role in development of HTF;\textsuperscript{63} SBP variability and successive variation of SBP were associated with HTF in patients who underwent IV thrombolysis.\textsuperscript{63}

### Hemodynamic Stroke with Low Perfusion
In animals, therapeutic approaches targeting enhancement of collateral circulation of intracranial arteries have shown better functional outcomes without significant complications.\textsuperscript{64} Those approaches include induced HT using phenylephrine (PE) infusion, intravascular volume expansion, cerebral arteriolar vasodilation, or CBF version using a head-down tilt. A study has investigated the effect of norepinephrine (NE) administration in patients with acute ischemic stroke within 24 hours from symptom onset.\textsuperscript{65} It was observed that NE-infusion-induced HT augments mean flow velocity were calculated using transcranial Doppler ultrasound. It was observed that NE-infusion-induced HT augmented mean Doppler flow velocities with concomitant elevation of intracranial pressure.\textsuperscript{66} However, to date, no high-quality randomized clinical trial has recommended the utility of catecholamine-induced HT in hemodynamic stroke.

### Intracerebral Hemorrhage

#### Hematoma Expansion in Intracerebral Hemorrhage
HT plays a more significant role in ICH compared with its effect in ischemic stroke.\textsuperscript{5} In addition to initial hemorrhage volume, HE is closely related with poor functional outcomes.\textsuperscript{15,68} HE is defined as an increased ICH volume by 33\% from the baseline and is reported in approximately up to 38\% of patients within the first 24 hours of symptom onset.\textsuperscript{69} Considering that the driving force of hemorrhage is hydrostatic pressure, BP reduction might be mechanistically helpful in reducing the risk of HE. Several nonrandomized observational studies have shown a possible benefit of BP reduction in patients with ICH.\textsuperscript{70,71} The concern associated with disproportionate BP lowering is precipitation of ischemia in the perihematomal area. However, several neuroimaging studies using positron emission tomography have shown that global or perihematomal CBF does not change significantly even with a 15\% reduction in MAP, suggesting that CA is relatively intact in patients with small ICH.\textsuperscript{72}

Another study used CT perfusion to assess possible CBF changes in perihematomal tissue in patients with ICH. The ICH Acutely Decreasing Arterial Pressure Trial included 75 patients and randomized them into two groups (SBP < 150 mm Hg and SBP < 180 mm Hg). CT perfusion was performed 2 hours after randomization and showed that perihematomal CBF was lower compared with the contralateral homologous region and that rapid reduction in BP did not decrease perihematomal CBF, suggesting that there is no penumbra in the perihematomal area.\textsuperscript{73} Several clinical trials have been performed to verify the safety and efficacy of BP reduction in patients with ICH.\textsuperscript{74–77}

### Clinical Trials
The Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) study was a feasibility trial using IV nicardipine in 60 patients with acute ICH. The results showed that acute BP reduction to 110 to 140 mm Hg was relatively safe.\textsuperscript{76} Although the neurological deterioration rate was higher in the intensive therapy group (target SBP of 110–140 mm Hg) than in the group with a target SBP of 140–170 mm Hg (tier 2) and the group with a target SBP of 170 to 200 mm Hg (tier 1), there was no temporal relationship observed between the infusion of IV nicardipine and the time of onset of neurological deterioration.

The Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT) compared the effect of BP lowering on HE.\textsuperscript{75} The 404 patients included in the trial were randomized to an intensive BP lowering group (target SBP < 140 mm Hg within 6 hours) and a guideline-based BP lowering group (SBP < 180 mm Hg). Results showed that intensive BP lowering produced a less proportional increase in hematoma volume. However, this trial was underpowered to show clinical benefit. The subsequent INTERACT2 trial involving 2,839 patients showed that intensive lowering of BP did not lead to significant reduction in poor functional outcomes or mortality, although a secondary outcome parameter using ordinal mRS analysis showed that intensive treatment was associated with better functional outcomes.\textsuperscript{74}

The ATACH-2 trial compared the effect of intensive BP reduction (SBP of 110–139 mm Hg) and modest BP reduction (SBP of 140–179 mm Hg) on functional outcomes in 1,000 patients with acute ICH.\textsuperscript{77} The majority of patients included demonstrated ICH in the basal ganglia and thalamus. Rapid BP reduction was attempted within 4.5 hours from stroke onset.
and maintained over the initial 24 hours of presentation using IV nicardipine infusion. The mean minimum SBP in the first 2 hours was observed to be 128.9 mm Hg (intensive group) and 141.1 mm Hg (standard treatment group), respectively. Results of the ATACH-2 trial show that intensive BP reduction to < 140 mm Hg (median 120 mm Hg) was not superior to maintaining an SBP of > 140 mm Hg (median 140 mm Hg) in terms of the proportion of mRS of 4 to 6 noted at 3 months and the rate of HE noted at 24 hours. In addition, the intensive BP reduction group showed a 2.3-fold higher incidence of adverse renal events than the standard group. Therefore, SBP reduction to a level < 140 mm Hg is not recommended because while aggressive BP reduction was not observed to be effective in improving functional outcomes, it did increase the risk of renal complications.

Conclusion

BP elevation is commonly associated with acute stroke and may be transient and may spontaneously decrease within several hours after presentation. The optimal target BP should be individualized based on the patient’s condition including stroke subtypes and treatment-related issues, such as thrombolytic modalities employed and recanalization status. For acute ICH, an SBP reduction to a level < 140 mm Hg is not necessarily recommended across the board.

References

17 Bösel J. Blood pressure control for acute severe ischemic and hemorrhagic stroke. Curr Opin Crit Care 2017;23(02):81–86
BP Management for Acute Ischemic and Hemorrhagic Stroke

Ko, Yoon

45 Mistry EA, Mistry AM, Nakawat MO, et al. Systolic blood pressure within 24 hours after thrombectomy for acute ischemic stroke correlates with outcome. J Am Heart Assoc 2017;6(05):e006167


